A number of technologies have been developed that optimize the process of managing blood sugar and administering insulin.
With the increase of diabetes across the globe, accurate and automated administration of insulin to patients with type 1 diabetes is a major need. The Continuous Glucose Monitoring (CGM) market is growing, with the number of people diagnosed with type 1 diabetes on the rise globally. Safe and efficient software for CGM and Artificial Pancreas (AP) systems will be important for companies growing and competing in this field.
This portfolio of technologies has been extensively developed in close collaboration with industry partners. Additionally, the portfolio has been the subject of numerous successful patient/clinical trials (described below) and are protected by a comprehensive patent estate.
An Enhanced Model Predictive Control for the Artificial Pancreas Using a Conficence Index Based on Residual Analysis of Past Predictions
UC Case no. 2016-315
An adaptive strategy for monitoring accurate glucose predictions that provides safe and effective glucose management and results in a significant reduction of hypoglycemia events. When compared to a static controller, this adaptive controller is able to avoid hypoglycemia more efficiently while the static controller has spurious episodes of hypoglycemia. U.S. and PCT patent applications pending. Learn more…
Strategy for Maintaining Blood Sugar Values for Subjects with Type 1 Diabetes within Defined (Glucose) Zone using Model Predictive Control
UC Case no. 2010-541
An artificial pancreas is created by using an automated zone model predictive control (Zone-MPC) with insulin and meal memory as a control approach to regulate glucose into the euglycemia range in order to manage meals with or without user intervention to a predefined glucose range. This fully automated process creates a seamless functional controller and shows the ability to handle both announced and unannounced meals without any further modification. This technology is covered by U.S. patent 8,762,070, as well as issued patents in EP, JP, GB, FR, DE and CA. Learn more…
Strategy for Maintaining Blood Glucose Concentrations for Subjects with Type 1 Diabetes within Multiple Defined (Glucose) Zones Using Model Predictive Control
UC Case no. 2011-227
A Multi Zone-MPC controller with embedded artificial insulin and meal memory is developed to regulate blood glucose to a predefined tunable zone with or without meal information. As a control approach, Multi-Zone-MPC is superior to standard set-point control due to the minimization of pump activity and more concentrated control effort. The use of four control zones has successfully proven to be a better control strategy that reduces the postprandial peaks and at the same time avoids any hypoglycemia due to efficient insulin administration. This technology is covered by U.S. Patent 9,700,708, in addition to issued patents in JP, throughout Europe, and Hong Kong. Learn more…
Daily Periodic Target-Zone Modulation in the Model Predictive Control Problem for Artificial Pancreas for Type 1 Diabetes Applications
UC Case no. 2013-384
A model predictive control (MPC) strategy to prevent a nocturnal hypoglycemic event using an Artificial Pancreas. The advantage of this MPC is that it employs periodic time- dependent target zones and insulin input constraints. This allows the safe operation of glycaemia controllers while the patient is sleeping and not able to intake glucose in the event of a hypoglycemic risk. This technology is covered by pending U.S. rights, as well as applications in EP, JP, KR, CH, CA and AU. Learn more…
This approach has potential to remove the need for clinician involvement before or during use of the AP. Results show a statistical significant reduction in HbA1c and hypoglycemia. This report shows a significant decrease of time in glucose <70 mg/dL and improvements in HbA1c.
This project represents the first home-use AP study testing system to component failure through extended use while also testing the safety and efficacy of the AP system. Results show the AP system is superior with reduced median glucose values, increased time in the target range, and a decrease in hypoglycemia. AP improved percent time 70-140 mg/dL (48.1 vs. 39.2%; P=0.016) and time 70-180 mg/dL (71.6 vs. 65.2%; P=0.008) and decreased median glucose (141 vs. 153 mg/dL; P=0.036).
This study looked at the effects of a one-time algorithmic adjustment of basal rate and insulin to carbohydrate ration open-loop settings on the performance of CLC. The CLC system proved robust and adaptable with minimal (<25%) time spent in the hypoglycemic range. The zone-MPC control algorithm eliminated nocturnal hypoglycemia. Median time in CLC was 25.3 hours. The median time in the 80-140mg/dl range was similar in both groups. Both groups showed minimal time spent less than 70 mg/dl (median 1.34% and 1.37%). There were no significant difference more than 140 mg/dl.
The first evaluation in adolescents of the Zone Model Predictive Control and Health Monitoring System (ZMPC+HMS) AP algorithms, and their first evaluation in a supervised outpatient setting with frequent exercise. The use of the ZMPC+HMS algorithms is feasible in the adolescent outpatient environment and achieved significantly more time in the desired glycemic range than sensor augmented pump (SAP) in the face of unannounced exercise and large announced meal challenges. The percentage of time with continuous glucose monitor (CGM) 70-180 mg/dL was 71%+/- 10% during CLC, compared to 57%+/- 16% during SAP. Nocturnal control during CPC was safe, with 0% of time with CGM<70mg/dL compared to 1.1% during SAP.
This study was performed to evaluate the safety and efficacy of a fully automated artificial pancreas using zone-model predictive control (zone-MPC) with the health monitoring system (HMS) during announced meals and overnight and exercise periods. The combination of the zone-MPC controller and the HMS hypoglycemia prevention algorithm was able to safely regulate glucose in a tight range with no adverse events despite the challenges of unannounced meals and moderate exercise. The HMS sent appropriate warnings to prevent hypoglycemia via short and multimedia message services, at an average of 3.8 treatments per subject.
|United States Of America||Published Application||19-0035507||01/13/2019||2016-315|